Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Nov 26, 2024

  • Pharmaceuticals
  • R&D

Roche Announces Update on Phase III SKYSCRAPER-01 Study

TOKYO, November 26, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that F. Hoffmann-La Roche Ltd. (SIX: RO, ROG; OTCQX: RHHBY) issued a Media Release today, regarding update on phase III SKYSCRAPER-01 study.

Please refer to the link below for details of the Roche’s Media Release:
Roche reports update on Phase III SKYSCRAPER-01 study results
https://www.roche.com/media/releases/med-cor-2024-11-26

[PDF 164KB]

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Hideki Sato
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp

Back